Literature DB >> 18061250

Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines.

T Michael Numnum1, Sharmila Makhija, Baogen Lu, Minghui Wang, Angel Rivera, Mariam Stoff-Khalili, Ronald D Alvarez, Zeng Bian Zhu, David T Curiel.   

Abstract

BACKGROUND: Hec1 (Highly Expressed in Cancer gene 1) has recently been shown to play an important role in the proper segregation of chromosomes during mitosis. Recently, an adenovirus delivery system carrying RNA interference (RNAi) of Hec1 has been reported in a cervical adenocarcinoma model. Adenoviral delivery systems, however, have the main limitation of poor viral infectivity due to lack of the native receptor, Coxsackie-Adenovirus Receptor (CAR), on the surface of tumor cells. We hypothesize that the viral infectivity of the adenovirus vector would be enhanced via a CAR-independent pathway by altering the targeting tropism, thus increasing the knockdown effect of Hec1 expression in ovarian carcinoma cells.
METHODS: Two adenoviruses (Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3), along with a negative control (Ad-siRNA-GAPDH.F5/3), were created using homologous recombination. HEY and SKOV3.ip1 cell lines were used to perform experiments. The following assays were then used to determine RNAi knockdown efficiency: (1) quantitative PCR (QPCR), (2) Western blot, (3) MTS assay, (4) Annexin V-FITC FACS, (5) crystal violet staining. In all experiments, a negative control served as a baseline measure.
RESULTS: QPCR demonstrated a 2-log viral infectivity enhancement with Ad-siRNA-Hec1.F5/3 over Ad-siRNA-Hec1. QPCR at 72 h revealed mRNA knockdown induced by Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cells, respectively (71%/60%, and 32%/78% mRNA knockdown compared to negative control). Western blot revealed translational inhibition induced by both Hec1 Ads with the least knockdown seen with Ad-siRNA-GAPDH.F5/3. FACS analysis revealed increased annexin V positivity in RNAi-infected cells, suggesting a higher rate of apoptosis. MTS assay indicated increased cell death 8 days post-infection with Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cell lines, respectively (75% vs. 35% and 43% vs. 12% viable cells). Crystal violet staining revealed increased cell death with Ad-siRNA-Hec1.F5/3 in all tested cell lines.
CONCLUSIONS: RNAi against Hec1 results in gene expression knockdown and apoptosis in vitro. The infectivity-enhanced adenovirus as delivery mechanism shows potential application in future gene therapy models of RNAi in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061250      PMCID: PMC2744403          DOI: 10.1016/j.ygyno.2007.08.096

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

1.  Role of adenovirus structural proteins in the cessation of host-cell biosynthetic functions.

Authors:  A J Levine; H S Ginsberg
Journal:  J Virol       Date:  1968-05       Impact factor: 5.103

2.  In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA.

Authors:  Mitsuo Yoshinouchi; Taketo Yamada; Masahiro Kizaki; Jin Fen; Takeyoshi Koseki; Yasuo Ikeda; Tatsuji Nishihara; Kenji Yamato
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

3.  Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.

Authors:  Zhenfeng Duan; Katherine A Brakora; Michael V Seiden
Journal:  Mol Cancer Ther       Date:  2004-07       Impact factor: 6.261

4.  Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.

Authors:  Mario Anders; Christine Christian; Martin McMahon; Frank McCormick; W Michael Korn
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

5.  AKT involvement in cisplatin chemoresistance of human uterine cancer cells.

Authors:  Véronique Gagnon; Isabelle Mathieu; Emilie Sexton; Kim Leblanc; Eric Asselin
Journal:  Gynecol Oncol       Date:  2004-09       Impact factor: 5.482

6.  Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.

Authors:  Anna Kanerva; Kurt R Zinn; Tandra R Chaudhuri; John T Lam; Kaori Suzuki; Taco G Uil; Tanja Hakkarainen; Gerd J Bauerschmitz; Minghui Wang; Bin Liu; Zhihong Cao; Ronald D Alvarez; David T Curiel; Akseli Hemminki
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454

7.  Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo.

Authors:  Hiroaki Uchida; Toshihiro Tanaka; Katsunori Sasaki; Kazunori Kato; Hironari Dehari; Yoshinori Ito; Masayoshi Kobune; Makoto Miyagishi; Kazunari Taira; Hideaki Tahara; Hirofumi Hamada
Journal:  Mol Ther       Date:  2004-07       Impact factor: 11.454

8.  Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage.

Authors:  Karolina Partheen; Kristina Levan; Lovisa Osterberg; Khalil Helou; György Horvath
Journal:  Genes Chromosomes Cancer       Date:  2004-08       Impact factor: 5.006

9.  Short-interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C translation initiation factors.

Authors:  Noboru Doi; Shuhei Zenno; Ryu Ueda; Hiroko Ohki-Hamazaki; Kumiko Ui-Tei; Kaoru Saigo
Journal:  Curr Biol       Date:  2003-01-08       Impact factor: 10.834

10.  Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.

Authors:  Gong Yang; Kathy Qi Cai; Jennifer A Thompson-Lanza; Robert C Bast; Jinsong Liu
Journal:  J Biol Chem       Date:  2003-11-18       Impact factor: 5.157

View more
  9 in total

1.  Downregulation of NUF2 inhibits tumor growth and induces apoptosis by regulating lncRNA AF339813.

Authors:  Peng Hu; Jianying Shangguan; Leida Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  [Expression of NUF2 in breast cancer and its clinical significance].

Authors:  Jingbo Sun; Jiawei Chen; Zhizhi Wang; Yunyao Deng; Lixin Liu; Xiaolong Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-05-30

3.  Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC.

Authors:  Y Tian; B Guo; H Jia; K Ji; Y Sun; Y Li; T Zhao; L Gao; Y Meng; D V Kalvakolanu; D J Kopecko; X Zhao; L Zhang; D Xu
Journal:  Cancer Gene Ther       Date:  2012-05-04       Impact factor: 5.987

4.  OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES.

Authors:  Marek Malecki; Raf Malecki
Journal:  Proc S Dak Acad Sci       Date:  2008

Review 5.  Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression.

Authors:  Song He; Dechun Zhang; Fang Cheng; Fanghong Gong; Yanan Guo
Journal:  Mol Biol Rep       Date:  2009-01-01       Impact factor: 2.316

6.  An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer.

Authors:  Geetika Sethi; Harsh B Pathak; Hong Zhang; Yan Zhou; Margret B Einarson; Vinod Vathipadiekal; Sumedha Gunewardena; Michael J Birrer; Andrew K Godwin
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

7.  siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo.

Authors:  Peng Hu; Xi Chen; Jing Sun; Ping Bie; Lei-Da Zhang
Journal:  Biosci Rep       Date:  2015-01-14       Impact factor: 3.840

8.  MiR-3613-3p affects cell proliferation and cell cycle in hepatocellular carcinoma.

Authors:  Donghui Zhang; Enqin Liu; Jian Kang; Xin Yang; Hong Liu
Journal:  Oncotarget       Date:  2017-10-10

9.  Bioinformatics analysis of SRSF1-controlled gene networks in colorectal cancer.

Authors:  Junxiu Sheng; Jinyao Zhao; Qiuhong Xu; Linlin Wang; Wenjing Zhang; Yang Zhang
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.